Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment
Ultromics, a leader in AI enabled cardiovascular imaging solutions, announced today that it has raised […]
Royal Wolverhampton NHS Trust (RWT) and Babylon bring digital-first, value-based healthcare to over 55,000 people across Wolverhampton
Royal Wolverhampton NHS Trust (RWT) and Babylon today announced they have extended their partnership to bring […]
New Drug Combo for Advanced Breast Cancer Approved for NHS in England
The National Institute of Health and Care Excellence (NICE) has approved the use of a […]
NHS Comment on Milestone of 75% of All Adults Double-Jabbed in England
NHS comment as the latest vaccine statistics published today show that 75% of people aged […]
NUHS Embarks on Holomedicine Research in Singapore, Using Mixed Reality (MR) Technology to Enhance Diagnosis, Education and Patient Care
To be able to literally “see inside” a patient’s skull and identify the location of […]
New Option to Treat Advanced Oesophageal Cancer Approved for NHS in Scotland
The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for patients with a type […]
AI Breakthrough for Faster, Cheaper and Injection-free Heart Scans
New artificial intelligence (AI) technology could lead to the next generation of heart MRI scans […]
BioNTech Plans Malaria Vaccine Based on Revolutionary Covid-19 Jab Technology
BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the launch of its Malaria project, which aims to […]
Diamyd Medical Secures Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes
The European Patent Office has informed Diamyd Medical that the Company’s patent application regarding prevention […]
Forxiga Approved in the EU for the Treatment of Chronic Kidney Disease in Patients With and Without Type-2 Diabetes
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more